The estimated Net Worth of James Rolke is at least 475 千$ dollars as of 9 January 2019. James Rolke owns over 1,600 units of La Jolla Pharmaceutical Co stock worth over 474,773$ and over the last 8 years James sold LJPC stock worth over 0$.
Sign up
James Rolke LJPC stock SEC Form 4 insiders trading
James has made over 2 trades of the La Jolla Pharmaceutical Co stock since 2018, according to the Form 4 filled with the SEC. Most recently James bought 1,600 units of LJPC stock worth 9,744$ on 9 January 2019.
The largest trade James's ever made was buying 1,600 units of La Jolla Pharmaceutical Co stock on 9 January 2019 worth over 9,744$. On average, James trades about 59 units every 3 days since 2017. As of 9 January 2019 James still owns at least 76,330 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of James Rolke stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Rolke's mailing address?
James's mailing address filed with the SEC is 10182 Telesis Ct, San Diego, CA 92121, USA.
Insiders trading at La Jolla Pharmaceutical Co
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over 13,460,170$ worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth 137,250,039$ . The most active insiders traders include Advisors Llcperceptive Life...、James N Topper、Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of 1,249,971$. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth 47,160$.
What does La Jolla Pharmaceutical Co do?
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
What does La Jolla Pharmaceutical Co's logo look like?
Complete history of James Rolke stock trades at La Jolla Pharmaceutical Co
La Jolla Pharmaceutical Co executives and stock owners
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include:
-
Larry G. Edwards,
Pres, CEO & Director -
Dr. Lakhmir S. Chawla,
Consultant -
Michael S. Hearne,
CFO & Sec. -
David Ramsay,
Independent Director -
Craig Johnson,
Independent Director -
Robert Rosen,
Independent Director -
Laura Douglass,
Independent Director -
Kevin Tang,
Chairman of the Board -
Michael Hearne,
Chief Financial Officer, principal financial officer, Principal Accounting Officer -
Larry Edwards,
President, Chief Executive Officer, Director -
Tony N. Hodges FACP, M.D.,
Chief Medical Officer -
Mark D. Williams,
Sr. VP of Medical Affairs -
Stewart M. Kroll,
Chief Devel. Officer -
Luke Seikkula,
Sr. VP of Pharmaceutical Operations -
Thomas Ouellette,
VP of Sales & Marketing -
Sandra Vedrick,
Sr. Director of Investor Relations & HR -
Paula Rusu,
VP of Operations -
Darryl Wellinghoff,
Chief Commercial Officer -
Dennis Mulroy,
Chief Financial Officer -
George F Tidmarsh,
President and CEO -
Laura L. Johnson,
Director -
James Rolke,
Chief Scientific Officer -
Lakhmir S Chawla,
Chief Medical Officer -
Kevin Ctang Capital Partner...,
-
Jennifer Carver,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Steven B Engle,
CEO & Chairman -
Deirdre Gillespie,
CEO -
Richard Reinisch,
-
Gail A Sloan,
Sen Dir of Finance/Controller -
Paul Jenn,
VP of Product Development -
W Leigh Md Phd Thompson,
Director -
Lisa I Koch,
Sr Dir Regulatory Affairs -
Saiid Zarrabian,
Director -
Matthew D Linnik,
CSO & Exec VP of Research -
Bruce K Jr Bennett,
VP of Manufacturing -
Teddi Reilly,
VP of Human Resources -
Andrew Wiseman,
Sen Dir Business Development -
William J Welch,
VP Sales & Marketing -
Luke Seikkula,
Vice President Manufacturing -
William R Ringo,
Director -
Kenneth R Heilbrunn,
VP of Clinical Development -
Robert Phd Fildes,
Director -
Craig R Smith,
Director -
William Engbers,
Director -
Josefina T Elchico,
Vice President Quality System -
Alejandro Gonzalez,
10% owner -
Michael James Byron Tansey,
Chief Medical Officer -
Healthcare V, Lp Frazier,
10% owner -
Thomas Phd Adams,
Director -
James N Topper,
Director -
Healthcare V, Lpfhm V, Llcf...,
-
Stephen Martin,
Director -
Bertrand C. Liang,
Director -
Woodlands Health Ventures F...,
10% owner -
Nader J Naini,
Director -
Niv Edward Caviar,
Chief Business Officer & CFO -
Martin P Sutter,
Director -
Woodlands Health Ventures F...,
10% owner -
Pharmaceutical Inc Biomarin,
10% owner -
Frank Young,
Director -
Kevin Ctang Capital Partner...,
Chief Financial Officer